ROSEN, A LEADING NATIONAL FIRM, Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Alvotech due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Alvotech securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Alvotech [2]. Group 2: Company Performance and Stock Impact - On November 2, 2025, Alvotech announced that the FDA issued a complete response letter for its Biologics License Application for AVT05, citing deficiencies from a pre-license inspection of its Reykjavik manufacturing facility [3]. - Following this announcement, Alvotech's stock price dropped by 34% on November 3, 2025, and nearly 4% on November 4, 2025 [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].